352 related articles for article (PubMed ID: 33096948)
1. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
2. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
3. Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
Yang Y; Meng Y; Ye J; Xia X; Wang H; Li L; Dong W; Jin D; Liu Y
J Control Release; 2018 Oct; 287():103-120. PubMed ID: 30144476
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
5. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
8. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
10. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Xiao Y; Wang S; Zong Q; Yin Z
AAPS PharmSciTech; 2018 Jul; 19(5):2395-2406. PubMed ID: 29869309
[TBL] [Abstract][Full Text] [Related]
12. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
13. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
14. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
15. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
16. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
[TBL] [Abstract][Full Text] [Related]
18. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel/IR1061-Co-Loaded Protein Nanoparticle for Tumor-Targeted and pH/NIR-II-Triggered Synergistic Photothermal-Chemotherapy.
He L; Qing F; Li M; Lan D
Int J Nanomedicine; 2020; 15():2337-2349. PubMed ID: 32308385
[TBL] [Abstract][Full Text] [Related]
20. Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo.
Deng W; Qiu J; Wang S; Yuan Z; Jia Y; Tan H; Lu J; Zheng R
Int J Nanomedicine; 2018; 13():439-453. PubMed ID: 29403275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
